Prothena Corporation plc (PRTA)


Stock Price Forecast

March 26, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Prothena Corporation plc chart...

About the Company

prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f

CEO

Gene Kinney

Exchange

NASDAQ

Website

http://www.prothena.com/

$311M

Total Revenue

148

Employees

$1B

Market Capitalization

-13.26

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PRTA News

Prothena Appoints David Ford to Newly Created Chief People Officer Position

24d ago, source: Yahoo Finance

DUBLIN, March 04, 2024--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein ...

Prothena Plc (NASDAQ: PRTA)

6d ago, source: The Motley Fool

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical ...

Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript

1mon ago, source: Yahoo Finance

Prothena Corporation plc misses on earnings expectations. Reported EPS is $-1.26 EPS, expectations were $-1.23. PRTA isn't one of the 30 most popular stocks among hedge funds at the end of the ...

PRTA Prothena Corporation plc

1mon ago, source: Seeking Alpha

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company ...

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense

1mon ago, source: Nasdaq

It had no debt as of the same date. Prothena Corporation plc Price, Consensus and EPS Surprise Revenues in 2023 totaled $91.4 million, up from $53.9 million in 2022. The figure, however ...

Prothena Corp PLC PRTA

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

1mon ago, source: Stockhouse

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported ...

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

1mon ago, source: Seeking Alpha

Prothena Corporation plc (NASDAQ:PRTA) is gearing up to report an update on its ongoing phase 1 study, using PRX012 for the treatment of patients with Alzheimer's Disease [AD]. It is expected that ...

Prothena to Participate in Upcoming Healthcare Conferences

23d ago, source: ADVFN

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...

Prothena to Participate in Jefferies 2023 Healthcare Conference

23d ago, source: ADVFN

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced ...

Prothena Corp PLC PRTA

14d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Prothena Corporation plc

6d ago, source: U.S. News & World Report

Analysts say these cheap stocks have plenty of upside.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...